Drug Development RFP
Drug Development RFP supports researchers and clinicians developing drugs and devices through IND-enabling studies and early clinical trials to advance treatments for Alzheimer’s disease and related dementias.
Browse similar grants
Funder: Alzheimer's Drug Discovery Foundation
Due Dates: December 7, 2026 (Invited Full Proposal, 5:00 p.m. ET)
Funding Amounts: Up to $5,000,000 per project; multi-year funding
Summary: Supports IND-enabling studies and early clinical trials of drugs and devices for Alzheimer’s disease and related dementias.
Key Information: Funding uses mission-related investments requiring return on investment based on scientific and/or business milestones.
Description
The Alzheimer’s Drug Discovery Foundation (ADDF) supports investigational new drug (IND)-enabling studies, or their international equivalent, and early-phase clinical trials for Alzheimer’s disease and related dementias. Eligible work includes phase 0 studies, phase 1 trials, and biomarker-based proof-of-concept studies, generally phase 1b or phase 2a. Regulatory preparation can include pharmacology, toxicology, pre-formulation, and manufacturing, including longer-term toxicology and manufacturing needed for later-stage trials.
The program prioritizes diverse mechanisms related to aging, including epigenetics, inflammation, mitochondrial and metabolic function, neuroprotection, proteostasis, synaptic activity, vascular function, and senescent cells. It considers novel, repurposed, and repositioned drugs, natural products, and devices. Modalities include small molecules, peptides, antibodies, gene therapies, antisense oligonucleotides, and stem cells. Strategic priorities include combination therapies and both disease-modifying and symptomatic agents.
